| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.krebsbiochem.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 281.58 Cr. | |
| Earnings per share (EPS) | -13.15 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 35.15 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | -14.10 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | -9.26 | Calculated using Price: 130.60 |
| Dividend Yield | 0.00 | Period Ending 2020-03 |
| No. of Shares Subscribed | 2.16 Cr. | 21,560,586 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Krebs Biochemicals & Industries (KBIL) was established in the year 1991 as a Public Limited Company with the main objective of establishing commercially viable biotech processes with applications in Medicine, Agriculture Industry. The company has pioneered in the fermentation technology over the last decade. KBIL went into public in the year March 1994 to part finance its fermentation technology project. KBIL has a strong shareholding community of over 10000 spread across all parts of the country. KBIL’s manufacturing Unit-I is located at Regadichelika Village, Nellore Dist., Andhra Pradesh, India. Products manufactured from Unit I facility are Ephedrine, Pseudoephedrine and their salts, which are used for making formulations for respiratory ailments, viz., cough, cold etc. The facility at Unit II is being used to manufacture a basket of fermentation products viz., Lovastatin, Simvastatin, (all cholesterol reducing agents) and Vitamin C and its salts (neutraceuticals), which has wider applications in pharma, feeds, foods beverages etc. The company is focussing on the research and development of new bio molecules and genetically engineered products by synthetic and biological approaches. The manufacturing facility is developed in an area of 83.79 acres and comprises of Administration Block, Fermentation Block, Extraction Column, Hydrogenation & Synthetic Blocks, Quality Control Department, Quality Assurance Block, Ware House, Pseudoephedrine Block, Solvent Yard and Canteen etc. KBIL has received ISO 9002 certification for its Unit-I situated at Nellore from Yarsley International Certifications Services accredited by United Kingdom Accreditation Services (U.K.A.S.) in the year 2001. Unit I is also accredited with European Certificate of Suitability from European Directorate for the Quality of Medicines (EDQM). Product range of the company includes: Bulk activities Synthetic Herbal
Intermediates
Products in pipeline
Achievements/ recognition:
|
||
Company Profile
Krebs Biochemicals & Industries (KBIL) was established in the year 1991 as a Public Limited Company with the main objective of establishing commercially viable biotech processes with applications in Medicine, Agriculture Industry. The company has pioneered in the fermentation technology over the last decade.
KBIL went into public in the year March 1994 to part finance its fermentation technology project. KBIL has a strong shareholding community of over 10000 spread across all parts of the country.
KBIL’s manufacturing Unit-I is located at Regadichelika Village, Nellore Dist., Andhra Pradesh, India. Products manufactured from Unit I facility are Ephedrine, Pseudoephedrine and their salts, which are used for making formulations for respiratory ailments, viz., cough, cold etc.
The facility at Unit II is being used to manufacture a basket of fermentation products viz., Lovastatin, Simvastatin, (all cholesterol reducing agents) and Vitamin C and its salts (neutraceuticals), which has wider applications in pharma, feeds, foods beverages etc. The company is focussing on the research and development of new bio molecules and genetically engineered products by synthetic and biological approaches. The manufacturing facility is developed in an area of 83.79 acres and comprises of Administration Block, Fermentation Block, Extraction Column, Hydrogenation & Synthetic Blocks, Quality Control Department, Quality Assurance Block, Ware House, Pseudoephedrine Block, Solvent Yard and Canteen etc.
KBIL has received ISO 9002 certification for its Unit-I situated at Nellore from Yarsley International Certifications Services accredited by United Kingdom Accreditation Services (U.K.A.S.) in the year 2001. Unit I is also accredited with European Certificate of Suitability from European Directorate for the Quality of Medicines (EDQM).
Product range of the company includes:
Bulk activities
Synthetic Lavastatin
Herbal
Intermediates
Products in pipeline
Achievements/ recognition:
| 1 Day |
|
-2.32% |
| 1 Week |
|
+13.57% |
| 1 Month |
|
+10.12% |
| 3 Month |
|
+3.45% |
| 6 Month |
|
+10.77% |
| 1 Year |
|
+56.03% |
| 2 Year |
|
+82.79% |
| 5 Year |
|
+69.72% |
| 9 years | 2012-03 | 2013-06 | 2014-09 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | -55.86 | -97.77 | -75.26 | -683.34 | -296.70 | |||||
| Return on Capital Employed (%) | -9.06 | -14.60 | -3.91 | -4.33 | -25.38 | -27.13 | -28.95 | -35.41 | -56.95 | |
| Return on Assets (%) | -11.46 | -10.72 | -3.19 | -6.44 | -14.60 | -13.46 | -14.38 | -14.92 | -20.91 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-06 Rs. Cr. | 2014-09 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 23 | 8 | 4 | 18 | 13 | 1 | -18 | -14 | -25 | |
| Non Curr. Liab. | 66 | 57 | 23 | 60 | 74 | 89 | 101 | 102 | 116 | |
| Curr. Liab. | 59 | 71 | 110 | 29 | 30 | 32 | 42 | 55 | 43 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 148 | 136 | 136 | 107 | 116 | 122 | 126 | 142 | 134 | |
| Non Curr. Assets | 105 | 97 | 98 | 92 | 107 | 109 | 109 | 111 | 115 | |
| Curr. Assets | 43 | 38 | 39 | 15 | 9 | 13 | 17 | 31 | 19 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 148 | 136 | 136 | 107 | 116 | 122 | 126 | 142 | 134 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-06 Rs. Cr. | 2014-09 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 71 | 11 | 1 | 4 | 34 | 48 | 33 | |||
| Other Income | 3 | 6 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
| Total Income | 74 | 18 | 0 | 0 | 2 | 4 | 34 | 48 | 34 | |
| Total Expenditure | -75 | -25 | -4 | -5 | -14 | -12 | -41 | -58 | -52 | |
| PBIDT | -1 | -7 | -4 | -5 | -11 | -8 | -7 | -9 | -18 | |
| Interest | -9 | -1 | 0 | -4 | -1 | -3 | -5 | -6 | -6 | |
| Depreciation | -10 | -8 | -2 | -4 | -4 | -4 | -4 | -5 | ||
| Taxation | 2 | 1 | 0 | |||||||
| Exceptional Items | 3 | 0 | 0 | -1 | 0 | |||||
| PAT | -17 | -15 | -4 | -8 | -16 | -16 | -18 | -20 | -29 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-06 Rs. Cr. | 2014-09 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 7 | -2 | 49 | -45 | -15 | -11 | -6 | 4 | -36 | |
| Cash Fr. Inv. | -1 | 6 | 0 | -3 | -4 | -5 | -3 | -4 | -9 | |
| Cash Fr. Finan. | -6 | -4 | -49 | 54 | 13 | 16 | 9 | 17 | 28 | |
| Net Change | 0 | 0 | 0 | 6 | -6 | 0 | 0 | 17 | -17 | |
| Cash & Cash Eqvt | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 17 | 0 |
|
Fri, 30 Jul 2021
Submission Of Quick Result For Quarter 30Th June 2021 We refer to the above mentioned subject we herewith submit to the Exchange the quick results for the quarter ended 30th June 2021 as approved by the Board of Directors at their meeting held on 30th July 2021. |
|
Fri, 30 Jul 2021
Board Meeting Outcome for Out Come Of Board Meeting we wish to inform the following outcome of the meeting of the Board of Directors held today i.e. 30th July 2021: (a) The Un-Audited financial results for the quarter ended 30th June 2021 along with the Limited Review Report thereon (Enclosed herewith) have been adopted by the Board. (b) The Board has taken note of Resignation of Mr. Manish Jain Director from the Board. (c) The Board has taken note of end of tenure of Mr. Avinash Ravi as Managing Director and accordingly Change in designation of Mr. Avinash Ravi from Managing Director to Non-Executive Director. (d) Appointment of Mr. Pabitra Bhattacharya as Additional Director and Managing Director of the Company subject to approval of members at the ensuing Annual General Meeting whose Brief profile is attached herewith. |
|
Fri, 23 Jul 2021
Update on board meeting KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2021 inter alia to consider and approve Update on board meeting we herewith intimate the Exchange that the meeting of Board of Directors of the Company is scheduled to be held on Friday 30th July 2021 to transact inter alia the following: 1. To consider and approve the unaudited financial results along with the Limited Review Report for the quarter ended 30th June 2021. 2. Any other matter with the permission of the Chair. |
| Fri, 30 Jul 2021 |
Close Within 2 Year High Zone
|
Either SRS Or ARS Going Below Zero
|
ATR Increasing for 3 Days
|
ATR Increasing for 5 Days
|
| Thu, 29 Jul 2021 |
Increasing Relative Strength - Sectoral Index
|
Equities
M.F.
Sectors